Synchronizing Care for Multi-Domain Psoriatic Disease

Key Takeaways:

• Over 50 percent of PsA patients present with 3 or more clinical domains simultaneously; a domain-based assessment rather than a simple joint count should be prioritized.
• Therapeutic choice should be guided by domain dominance; IL-17 inhibitors excel in axial disease, while IL-23 and JAK inhibitors offer potent peripheral and skin clearance.
• Effective inflammation control across all domains is a critical component of managing comorbidities.

The clinical landscape of psoriatic disease has shifted from a focus on skin and joints to a sophisticated understanding of a systemic, multi-domain inflammatory condition. Psoriatic arthritis (PsA) is no longer viewed as a singular entity but as a heterogeneous manifestation of psoriatic disease that can simultaneously impact peripheral joints, the axial skeleton, entheses, dactylitis, skin, and nails.¹

For the clinician, the challenge lies in the fact that these domains rarely respond uniformly to a single therapeutic intervention. Achieving minimal disease activity (MDA) requires a synchronized, domain-based approach to management that integrates the latest treatment guidelines while prioritizing the patient’s most debilitating symptoms.¹

The 6 domains of psoriatic disease

Understanding the diversity of PsA manifestations is the first step in synchronizing care. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) identifies 6 key clinical domains:^1,2

• Peripheral arthritis – Characterized by pain, swelling, and stiffness in the small and large joints
• Axial disease – Inflammatory back pain and sacroiliitis, often mimicking ankylosing spondylitis
• Enthesitis – Inflammation at the sites where tendons or ligaments insert into bone (e.g., Achilles tendon)
• Dactylitis – "Sausage digits" involving the entire finger or toe, representing a mix of tenosynovitis and joint inflammation
• Psoriasis – Ranging from plaque psoriasis to more severe erythrodermic variants
• Nail disease – Pitting, onycholysis, and crumbling, which are strong predictors of future joint involvement

Recent studies emphasize that more than 50 percent of patients with PsA exhibit involvement in 3 or more of these domains simultaneously. This multi-domain involvement is associated with a significantly higher burden of disease and reduced quality of life.³

Therapeutic sequencing and precision medicine

The cornerstone of modern PsA management is the "treat-to-target" strategy. However, choosing the right biological or synthetic disease-modifying antirheumatic drug (DMARD) requires a nuanced understanding of which pathways (TNF, IL-17, IL-23, or JAK) are most effective for specific domains.^1,3

Navigating the "domain-dominant" strategy

Current 2024 updates to clinical practice suggest a domain-dominant approach to therapy selection. For instance:^4,5

• IL-17 inhibitors – Highly effective for axial disease and skin manifestations, making them a primary choice for patients with significant spinal involvement
• IL-23 inhibitors – While exceptionally potent for skin and peripheral arthritis, they have shown less efficacy in purely axial PsA compared to IL-17 inhibitors.
• JAK inhibitors – Offer a versatile oral option that addresses peripheral joints and enthesitis effectively, though safety profiles regarding cardiovascular risk must be considered
• Combination strategies – For difficult-to-treat PsA, clinicians are increasingly utilizing dual-pathway inhibition or targeted combinations.

Addressing the "invisible" burden: Comorbidities

Synchronizing care extends beyond the musculoskeletal system. PsA is inextricably linked to cardiometabolic comorbidities, including obesity, Type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD).^6,7

Chronic systemic inflammation in PsA accelerates atherosclerosis. Recent evidence suggests that effectively controlling joint and skin inflammation with TNF or IL-17 inhibitors may reduce the risk of major adverse cardiovascular events (MACE). Clinicians must therefore view PsA management as a form of cardiovascular risk modification.⁶

Screening for depression and anxiety is vital as well. These conditions are present in nearly one-third of PsA patients and can significantly lower the perceived efficacy of treatment.⁸

Beyond psychological distress, fatigue and sleep disorders are pervasive but frequently under-reported. Addressing these symptoms is essential, as sleep deprivation has been shown to trigger a pro-inflammatory cycle.

The multidisciplinary care model

The complexity of multi-domain disease necessitates a collaborative "hub-and-spoke" model of care. The ideal synchronization occurs when rheumatologists work in tandem with dermatologists, cardiologists, and physical therapists.^1,9

Research indicates that "combined clinics" – where patients see both a rheumatologist and a dermatologist in a single visit – result in faster time-to-treatment, higher rates of MDA attainment, and improved patient satisfaction. This collaboration ensures that a drug chosen for joint health does not inadvertently ignore a burgeoning skin flare or exacerbate a comorbid condition.⁹

Moving past a “one-size-fits-all” mentality

Synchronizing care for multi-domain psoriatic disease requires moving beyond a "one-size-fits-all" mentality. By identifying dominant clinical domains, selecting targeted therapies based on the latest trial data, and managing systemic comorbidities, clinicians can fundamentally alter the disease trajectory for their patients. The goal is no longer just "improvement," but the comprehensive suppression of inflammation across all tissues.^1,9